[Observation on the effects of the treatment of sillicosis merger asthma].

OBJECTIVE: To investigate Salmeterol/Fluticasone Propionate and Totropiumi treatment of Sillicosis merger Asthma. METHODS: 30 patients with Sillicosis merger Asthma were randomly divided into group Salmeterol/Fluticasone Propionate( Single group) ( n=14) and group Salmeterol/Fluticasone Propionate and Totropiumi (Joint group) ( n= 16), patient in single group were only given Salmeterol/Fluticasone Propionate (50 f.Lg Bid) inhaling,and those in Joint group were given Salmeterol/Fluticasone Propionate (50 f.Lg Bid) and Totropiumi ( 18 f.Lg Qd) inhaling. The treatment was last for 6 months.Before the treatment,evaluation of the two groups of Sillicosis installment,determination their foungation lung function and ACT score .. After the cause of treatment, lung function FEV10/FVC(% ), FEV10 pred%, FEV10(ml), ACT score, the incidence of side effects of two groups were compared and analyzed. RESULT: The two groups before the treatment of lung fuction and ACT score had no statistically significant difference. The two groups after treatment of lung fuction FEV10/FVC (% ),FEV10 pred%, ACT score obviously higher than before treatment (P<0.05), Joint group in FEV1/FVC(% ), ACT score significantly higher than in Single group (?<0.05), Joint group acute attack times(0.98±0.79)/time lower than Single group (2.10 ± 0.81 )/time (t=3.86,P<0.05). There were no significant side effect in two groups. CONCLUSION: Salmeterol/Fluticasone Propionate or the combination of Salmeterol/Fluticasone Propionate and Totropiumi can improve lung function and clinical symptoms of patients with Sillicosis merger Asthma. It is also better that the combination of Salmeterol/Fluticasone Propionate and Totropiumi obviously improve clinical symptoms of patients and reduice acute attack times.

RHAMM regulates the growth and migration of lung adenocarcinoma A549 cell line by regulating Cdc2/CyclinB1 and MMP9 genes Running title: RHAMM regulates the growth of lung adenocarcinoma cells.

Objective: The study aims to explore the effects of receptor of hyaluronan mediated motility (RHAMM) on the proliferation, invasion and migration of the lung adenocarcinoma (LUAD) cell line A549 and its targeted regulatory pathway. Methods: Bioinformatics was used to analyze the differentially expressed genes in LUAD chips. The mRNA and protein expression level of Cdc2, CyclinB1, MMPs and epithelial-mesenchymal transition (EMT) related markers E-cadherin and Vimentin were tested by qRT-PCR and western blot in A549 cell line after silencing RHAMM. Cell proliferation, cell division cycle, migration and invasion abilities were tested in RHAMM knockdown A549 cells by flow cytometry and in vitro assays. Results: Silencing RHAMM inhibited EMT, proliferation, migration and invasion of A549 cell line and induced cells to cluster at G2/M phase. In addition, after silencing RHAMM, the mRNA and protein expressions of Cdc2 and CyclinB1 were decreased while those of MMP9 were increased. Conclusion: The findings suggest that RHAMM regulates cell division cycle by regulating Cdc2 and CyclinB1, and regulates extracellular matrix degradation by regulating MMP9. These targeted modulations regulate the occurrence and development of LUAD cells.

Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer.

BACKGROUND: Patients with previously treated non-small-cell lung cancer (NSCLC) have limited treatment options. A novel treatment based on programmed death 1 (PD-1)/programed death ligand 1 (PD-L1) inhibitors has emerged as promising therapeutic options for advanced NSCLC. We assessed oncological outcomes of PD-L1 antibody versus docetaxel in previously treated NSCLC. OBJECTIVES: The purpose of this meta-analysis was to analyse the oncological outcomes of anti-PD1 to chemotherapy in the treatment of non-small-cell lung cancer. RESULTS: Overall survival (OR=0.68,95%CI=0.61-0.75, P<0.00001) and progression-free survival (OR=0.84,95%CI=0.77-0.92, P=0.0002) were longer with anti-PD1 than with docetaxel in NSCLC. Anti-PD1 was associated with even greater objective response rate than docetaxel (OR=1.61,95%CI=1.16-2.24, P=0.004). Treatment-related adverse events of grade 3-5 did favor anti-PD1 over docetaxel (OR=0.21,95%CI=0.10-0.42, P<0.00001). CONCLUSIONS: Among patients with advanced NSCLC, we found that there was a superior survival benefit and with a favorable safety profile with anti-PD1 than with docetaxel. More large-scale randomized controlled trials are needed to identify relevant biomarkers that have an effect on predicting the population that would most likely benefit from PD-1/PD-L1 for pretreated advanced NSCLC patients.